🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Chinese SLE Treatment And Research Group clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Chinese SLE Treatment And Research Group as lead sponsor. Synced 26 Sep 2026
13Current trials
6Recruiting now
13Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Chinese SLE Treatment And Research Group is the lead sponsor of 13 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 4. The drugs named most often in its trials are Telitacicept, Sirolimus and Adalimumab. The most-studied condition is Lupus Erythematosus, Systemic.

ClinicalTrials.gov trials by status

  • Recruiting646%
  • Not yet open538%
  • Active, closed215%

Trials by phase

  • Phase 4754%
  • Phase 2/3215%
  • Observational215%
  • Phase 318%
  • Phase 118%
01

Clinical trials sponsored by Chinese SLE Treatment And Research Group

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
NCT05965284 · ClinicalTrials.gov ↗ · ANCA-associated Vasculitis, Maintenance Therapy
Phase 4 Recruiting 2023-03 China
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174 · ClinicalTrials.gov ↗ · Lupus Nephritis
Observational Recruiting 2023-12 China
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
NCT05962840 · ClinicalTrials.gov ↗ · ANCA Associated Vasculitis
Phase 4 Recruiting 2023-06 China
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
NCT06881290 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic
Phase 1 Recruiting 2025-05 China
Chinese Rheumatism Biobank(CRB)
NCT06887517 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic
Observational Recruiting 2025-02 China
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
NCT07657793 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Immune Thrombocytopenia
Drug: Sirolimus
Phase 2/3 Recruiting 2026-06 China
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
NCT07814664 · ClinicalTrials.gov ↗ · Systemic Lupus Erthematosus
Phase 2/3 Not yet open 2026-10 China
Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
NCT07451665 · ClinicalTrials.gov ↗ · Takayasu Arteritis (TAK)
Phase 4 Not yet open 2026-04 China
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
NCT07013838 · ClinicalTrials.gov ↗ · Takayasu Arteritis (TAK)
Phase 4 Not yet open 2025-06 China
Telitacicept for the Treatment of Refractory RA
NCT07008196 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA)
Phase 4 Not yet open 2025-06 China
Treatment Strategy for Patients With RA-ILD
NCT07643038 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis Associated Interstitial Lung Disease
Phase 4 Not yet open 2026-09 China
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
NCT07381465 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic
Phase 4 Active, closed 2026-06 China
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus
Drug: Sirolimus
Phase 3 Active, closed 2021-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Chinese SLE Treatment And Research Group trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Chinese SLE Treatment And Research Group trials

11 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China136

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Lupus Erythematosus, Systemic

SponsorTrials
Viatris Innovation4

Sponsors with the most current trials registered for this condition.

06

Questions about Chinese SLE Treatment And Research Group trials

How many clinical trials does Chinese SLE Treatment And Research Group sponsor?

Chinese SLE Treatment And Research Group is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chinese SLE Treatment And Research Group trials recruiting?

Yes. 6 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chinese SLE Treatment And Research Group testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Telitacicept (3), Sirolimus (2), Adalimumab (1), Azathioprine (1) and Deucravacitinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.